Investigating how GTP metabolism affects aggressive brain tumors.
Therapeutic resistance and aggressive malignancy in glioblastomas: the contribution of GTP metabolism through regulation by IMPDH2
This study is looking at how a specific process in brain tumors called glioblastoma multiforme affects their growth and resistance to treatment, with the hope of finding new ways to help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10894312 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma multiforme (GBM), the most aggressive type of brain tumor, and aims to understand how GTP metabolism contributes to its growth and treatment resistance. The researchers will explore the role of inosine monophosphate dehydrogenase-2 (IMPDH2) in GTP synthesis, which is crucial for the proliferation of GBM cells. By identifying unique metabolic pathways in these tumors, the study seeks to uncover potential new targets for therapy that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma multiforme who are seeking new treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While there have been incremental improvements in glioblastoma treatment, this research explores novel metabolic pathways that have not been extensively tested in clinical settings.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Sasaki, Atsuo — University of Cincinnati
- Study coordinator: Sasaki, Atsuo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.